Zhaogang Liu

机构：Shandong First Medical University

发表论文 18 篇 · 总被引 165 次 · h-index 7

代表论文

• Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial (2024 · Nature Communications · 被引 38)
• Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization (2019 · International Journal of Biological Sciences · 被引 32)
• Concomitant NAFLD Facilitates Liver Metastases and PD-1-Refractory by Recruiting MDSCs via CXCL5/CXCR2 in Colorectal Cancer (2024 · Cellular and Molecular Gastroenterology and Hepatology · 被引 24)
• Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients (2023 · BMC Cancer · 被引 18)
• 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies (2016 · Bioorganic & Medicinal Chemistry · 被引 17)
• Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids (2016 · Bioorganic & Medicinal Chemistry Letters · 被引 13)